YMAB Y-mAbs Therapeutics, Inc. Stock Quote

YMAB [NASD]

Index	-	P/E	-	EPS (ttm)	-1.57	Insider Own	0.60%	Shs Outstand	41.87M	Perf Week	9.21%
Market Cap	1.60B	Forward P/E	-	EPS next Y	-1.42	Insider Trans	-76.02%	Shs Float	36.19M	Perf Month	15.94%
Income	-59.70M	PEG	-	EPS next Q	-0.66	Inst Own	67.30%	Short Float	8.64%	Perf Quarter	0.75%
Sales	26.10M	P/S	61.35	EPS this Y	-29.20%	Inst Trans	16.04%	Short Ratio	10.40	Perf Half Y	-28.56%
Book/sh	6.02	P/B	6.03	EPS next Y	-32.70%	ROA	-33.30%	Target Price	57.88	Perf Year	-11.21%
Cash/sh	5.72	P/C	6.35	EPS next 5Y	-	ROE	-38.50%	52W Range	24.77 - 55.22	Perf YTD	-26.70%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-113.40%	52W High	-34.28%	Beta	-
Dividend %	-	Quick Ratio	15.50	Sales past 5Y	-	Gross Margin	99.60%	52W Low	46.48%	ATR	2.05
Employees	125	Current Ratio	15.50	Sales Q/Q	-	Oper. Margin	-	RSI (14)	58.18	Volatility	6.11% 5.43%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	214.30%	Profit Margin	-	Rel Volume	0.76	Prev Close	37.53
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 06 AMC	Payout	-	Avg Volume	300.48K	Price	36.29
Recom	1.60	SMA20	3.42%	SMA50	16.28%	SMA200	-9.63%	Volume	229,070	Change	-3.30%

May-07-21

Upgrade

BofA Securities

Neutral → Buy

Apr-23-21

Resumed

Cowen

Outperform

Mar-22-21

Resumed

JP Morgan

Overweight

$57 → $52

Jan-15-21

Downgrade

BofA Securities

Buy → Neutral

$56

Nov-09-20

Reiterated

H.C. Wainwright

Buy

$52 → $65

May-05-20

Initiated

Barclays

Overweight

$44

May-01-20

Initiated

Janney

Buy

Apr-29-20

Initiated

Morgan Stanley

Equal-Weight

Dec-24-19

Initiated

JP Morgan

Overweight

$39

Nov-20-19

Initiated

Guggenheim

Buy

Sep-04-19

Initiated

Wedbush

Outperform

Apr-01-19

Initiated

H.C. Wainwright

Buy

$36

Oct-16-18

Initiated

BTIG Research

Buy

$35

Oct-16-18

Initiated

BofA/Merrill

Buy

$26

Jun-04-21 09:05AM	Y-mAbs Announces Frontline Data for DANYELZA® (naxitamab-gqgk) in High-Risk Neuroblastoma GlobeNewswire
09:00AM	Y-mAbs Announces Update on Omburtamab for DIPG GlobeNewswire
May-20-21 12:30PM	Y-mAbs Signs Antibodies Distribution Deal With Adium; Street Says Buy SmarterAnalyst +7.42%
May-19-21 04:01PM	Y-mAbs Enters into Exclusive Distribution Agreement with Adium Pharma S.A. for DANYELZA® (naxitamab-gqgk) and Omburtamab in Latin America GlobeNewswire
May-13-21 09:00AM	Y-mAbs Announces Update on SADA Technology GlobeNewswire
May-07-21 07:15AM	Y-mAbs Therapeutics, Inc. to Host Earnings Call ACCESSWIRE +19.37%
May-06-21 05:50PM	YmAbs Therapeutics, Inc. (YMAB) Surpasses Q1 Earnings Estimates Zacks
04:01PM	Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments GlobeNewswire
Apr-29-21 04:01PM	Y-mAbs to Announce First Quarter 2021 Financial and Operating Results on May 6, 2021 GlobeNewswire
09:00AM	Y-mAbs Announces Data to be Presented at 2021 ASCO Annual Meeting GlobeNewswire
Apr-27-21 04:01PM	Y-mAbs Submits Omburtamab Marketing Authorization Application to the European Medicines Agency GlobeNewswire
Apr-23-21 07:27AM	When Will Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Breakeven? Simply Wall St.
Apr-20-21 12:18PM	Y-mAbs Asked To Submit Additional Granularity Of Data For Omburtamab In Nerve Tissue Cancer Benzinga
09:00AM	Y-mAbs Provides Regulatory Update on Omburtamab GlobeNewswire
Apr-12-21 09:00AM	Y-mAbs Announces GPA33-SADA Data Presented at AACR GlobeNewswire
Apr-09-21 10:24AM	JPMorgan Says These 2 Stocks Could Surge Over 80% TipRanks -7.41%
Feb-28-21 11:46PM	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Analysts Are Reducing Their Forecasts For This Year Simply Wall St.
Feb-26-21 06:45AM	Y-mAbs Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-25-21 04:01PM	Y-mAbs Announces 2020 Financial Results and Recent Corporate Developments GlobeNewswire -7.73%
04:50AM	Could The Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Ownership Structure Tell Us Something Useful? Simply Wall St.
Feb-22-21 04:01PM	Y-mAbs Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares GlobeNewswire -5.37%
Feb-19-21 09:00AM	Y-mAbs to Announce 2020 Financial and Operating Results on February 25, 2021 GlobeNewswire
Feb-18-21 05:20AM	Y-mAbs Therapeutics Raises $100M Via Equity To Fund Commercial Rollout Of Neuroblastoma Med Benzinga
Feb-17-21 07:14PM	Y-mAbs Announces Pricing of Public Offering of Common Stock GlobeNewswire -8.98%
Feb-16-21 04:01PM	Y-mAbs Announces Proposed Public Offering of Common Stock GlobeNewswire
Jan-06-21 09:00AM	Y-mAbs Therapeutics to Present At 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-28-20 09:00AM	Y-mAbs Announces Sale of Priority Review Voucher GlobeNewswire -5.27%
Dec-18-20 09:05AM	Y-mAbs Signs License Agreement with SciClone for DANYELZA® (naxitamab-gqgk) and Omburtamab in China GlobeNewswire
09:00AM	Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA® (naxitamab-gqgk) and Omburtamab in Eastern Europe GlobeNewswire
Dec-16-20 09:00AM	Y-mAbs Announces Pipeline Update GlobeNewswire
Dec-10-20 04:50PM	Is YMAB A Good Stock To Buy Now? Insider Monkey
Dec-09-20 09:00AM	Y-mAbs Announces Update on DANYELZA® (naxitamab-gqgk) at ESMO GlobeNewswire
Dec-07-20 09:00AM	Y-mAbs to Host Virtual Research & Development Day on Wednesday, December 16 GlobeNewswire
Dec-04-20 12:06PM	Insider Sells Y-mAbs Therapeutics Stock Benzinga
09:00AM	Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in Israel GlobeNewswire
Nov-25-20 05:02PM	FDA Approves Y-mAbs DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma GlobeNewswire
Nov-19-20 09:00AM	Y-mAbs Announces Update on Omburtamab in DIPG GlobeNewswire
Nov-06-20 04:01PM	YmAbs Therapeutics, Inc. (YMAB) Q3 2020 Earnings Call Transcript Motley Fool
Nov-05-20 04:01PM	Y-mAbs Announces Third Quarter 2020 Financial Results and Recent Corporate Developments GlobeNewswire
Oct-29-20 09:00AM	Y-mAbs to Announce Third Quarter 2020 Financial and Operating Results on November 5, 2020 GlobeNewswire
Oct-28-20 03:02PM	We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate Simply Wall St.
Oct-26-20 09:10AM	Y-mAbs Announces FDA Clearance of IND for Lutetium-177 Labeled Omburtamab Antibody for Adult Indications GlobeNewswire
Oct-16-20 09:00AM	Y-mAbs Announces Update on Naxitamab and Omburtamab in Neuroblastoma GlobeNewswire
Oct-14-20 09:00AM	Y-mAbs Announces FDA Clearance of IND for its Lutetium-177 Labeled Omburtamab Antibody GlobeNewswire
Oct-09-20 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Evolus, Lizhi, Iovance Biotherapeutics, and Y-mAbs Therapeutics and Encourages Investors to Contact the Firm GlobeNewswire
Oct-08-20 05:34PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Y-mAbs Therapeutics, Inc. - YMAB PR Newswire
01:05PM	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Y-mAbs Therapeutics, Inc. (YMAB) Investigation ACCESSWIRE
Oct-07-20 09:00AM	Y-mAbs Nivatrotamab for the Treatment of Patients with Neuroblastoma Granted Orphan Drug Designation and Rare Pediatric Disease Designation by FDA GlobeNewswire +7.45%
Oct-06-20 08:24AM	The Daily Biotech Pulse: Pfizer, BioNTech Begin European Filing For Coronavirus Vaccine, Y-mAbs BLA Rejected, GlycoMimetics Granted Rare Pediatric Disease Designation Benzinga -8.56%
Oct-05-20 04:01PM	Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma GlobeNewswire +7.28%
Aug-06-20 04:01PM	Y-mAbs Announces Second Quarter 2020 Financial Results and Recent Corporate Developments GlobeNewswire
09:00AM	Y-mAbs Announces Completion of Submission of Omburtamab Biologics License Application to FDA GlobeNewswire
Aug-04-20 09:00AM	Y-mAbs to Announce Second Quarter 2020 Financial and Operating Results on August 6, 2020 GlobeNewswire
Jul-27-20 04:01PM	Y-mAbs Announces Data to be Presented at 2020 SIOP GlobeNewswire +6.46%
Jul-14-20 09:00AM	Y-mAbs Announces Update on SADA Technology and New Preclinical SADA Construct GlobeNewswire
Jul-05-20 03:05PM	Y-mAbs Therapeutics, Inc. (YMAB): Are Hedge Funds Right About This Stock? Insider Monkey
Jun-30-20 04:01PM	Y-mAbs Announces Initiation of Submission of Omburtamab Rolling Biologics License Application to the FDA GlobeNewswire -5.41%
Jun-02-20 09:00AM	Y-mAbs Announces U.S. FDA Acceptance of Biologics License Application for Danyelza (naxitamab) for the Treatment of Neuroblastoma for Priority Review GlobeNewswire
May-22-20 11:58AM	Should You Own This Sleeper Biotech Stock? Motley Fool
May-13-20 09:00AM	Y-mAbs Announces Data to be Presented at 2020 ASCO Annual Meeting GlobeNewswire
May-11-20 06:53AM	H.C. Wainwright Sticks to Their Buy Rating for Y-Mabs Therapeutics Inc Investing.com
May-09-20 02:00PM	YmAbs Therapeutics, Inc. (YMAB) Q1 2020 Earnings Call Transcript Motley Fool
May-07-20 04:01PM	Y-mAbs Announces First Quarter 2020 Financial Results and Recent Corporate Developments GlobeNewswire
12:26PM	Was The Smart Money Right About Y-mAbs Therapeutics, Inc. (YMAB)? Insider Monkey
Apr-30-20 09:56AM	UPDATE - Y-mAbs to Announce First Quarter 2020 Financial and Operating Results on May 7, 2020 GlobeNewswire
09:00AM	Y-mAbs to Announce 2019 Financial and Operating Results on May 7, 2020 GlobeNewswire
Apr-28-20 12:51PM	We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth Simply Wall St.
Apr-24-20 09:00AM	Y-mAbs Announces Appointment of Laura J. Hamill to its Board of Directors GlobeNewswire
Apr-15-20 09:22AM	Y-mAbs enters into Worldwide Exclusive License Agreement for SADA Technology a Novel Radioimmunotherapy Platform GlobeNewswire
Apr-01-20 09:00AM	Y-mAbs Announces Submission of Naxitamab Biologics License Application to U.S. FDA GlobeNewswire -5.17%
Mar-12-20 04:01PM	Y-mAbs Announces 2019 Financial Results and Recent Corporate Developments GlobeNewswire -14.45%
02:30PM	Y-mAbs Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-05-20 09:00AM	Y-mAbs to Announce 2019 Financial and Operating Results on March 12, 2020 GlobeNewswire -6.10%
Feb-26-20 04:01PM	Y-mAbs Announces Positive Pre-BLA Meeting with FDA for Omburtamab GlobeNewswire
Jan-07-20 09:00AM	Y-mAbs Therapeutics To Present At 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-24-19 08:13AM	Benzinga Pro's Top 5 Stocks To Watch For Tues., Dec. 24, 2019: TSLA, WCC, ACST, YMAB, ITCI Benzinga
Dec-16-19 01:48PM	Is Y-mAbs Therapeutics, Inc. (YMAB) A Good Stock To Buy? Insider Monkey
Dec-12-19 09:00AM	Y-mAbs GD2-GD3 Vaccine Granted Rare Pediatric Disease Designation GlobeNewswire
Dec-11-19 09:00AM	Y-mAbs Announces Positive Naxitamab Frontline Data GlobeNewswire
Dec-05-19 04:01PM	Y-mAbs and the European Medicines Agency Pediatric Committee Reach Agreement on the Pediatric Investigation Plan for Omburtamab GlobeNewswire
09:00AM	Y-mAbs to Host R&D Event and Live Webcast on Wednesday, December 11 GlobeNewswire
Nov-29-19 09:00AM	Y-mAbs Initiates Rolling Submission of Biologics License Application to U.S. FDA for Naxitamab for Treatment of Neuroblastoma GlobeNewswire
Nov-15-19 09:03AM	Y-mAbs Announces Update on Omburtamab in DSRCT GlobeNewswire
Nov-13-19 04:01PM	Y-mAbs Announces Third Quarter 2019 Financial Results and Recent Corporate Developments GlobeNewswire
Nov-06-19 04:05PM	Y-mAbs to Announce Third Quarter 2019 Financial and Operating Results on November 13 GlobeNewswire
Nov-01-19 04:05PM	Y-mAbs Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares GlobeNewswire -5.62%
11:00AM	Y-mAbs Flags Potential Delay In Pre-BLA Meeting, Sticks To Regulatory Filing Timeline Benzinga
Oct-30-19 08:20PM	Heres What Hedge Funds Think About Y-mAbs Therapeutics, Inc. (YMAB) Insider Monkey -10.13%
Oct-29-19 09:14PM	Y-mAbs Announces Pricing of Public Offering of Common Stock GlobeNewswire
04:40PM	Y-mAbs Announces Proposed Public Offering of Common Stock GlobeNewswire
07:32AM	The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study Benzinga
Oct-28-19 10:42AM	We're Not Very Worried About Y-mAbs Therapeutics's (NASDAQ:YMAB) Cash Burn Rate Simply Wall St.
09:00AM	Y-mAbs Announces Positive Omburtamab Clinical Data GlobeNewswire
Oct-25-19 09:14AM	Y-mAbs Announces Naxitamab Update GlobeNewswire
Sep-04-19 03:09PM	Wedbush: Y-mAbs Could Attract Investor Attention As Market Volatility Grows Benzinga
Aug-30-19 09:00AM	Y-mAbs Announces Data to be Presented at 2019 CTOS GlobeNewswire
Aug-14-19 10:23PM	YmAbs Therapeutics, Inc. (YMAB) Q2 2019 Earnings Call Transcript Motley Fool
04:05PM	Y-mAbs Announces Second Quarter 2019 Financial Results and Recent Corporate Developments GlobeNewswire
Aug-08-19 01:36PM	How Much Of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Do Insiders Own? Simply Wall St.
Aug-07-19 04:15PM	Y-mAbs to Announce Second Quarter 2019 Financial and Operating Results on August 14 GlobeNewswire

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WG Biotech ApS	Director	Jun 10	Sale	36.15	11,229	405,971	4,178,456	Jun 11 05:01 PM
Wedell-Wedellsborg Johan	Director	Jun 10	Sale	36.15	11,229	405,971	4,178,465	Jun 11 05:00 PM
WG Biotech ApS	Director	Jun 09	Sale	36.19	116,700	4,223,116	4,189,694	Jun 10 07:00 PM
Wedell-Wedellsborg Johan	Director	Jun 09	Sale	36.19	116,700	4,223,116	4,189,694	Jun 10 06:35 PM
Wedell-Wedellsborg Johan	Director	Jun 08	Sale	35.28	33,300	1,174,694	4,306,394	Jun 10 06:35 PM
WG Biotech ApS	Director	Jun 08	Sale	35.28	33,300	1,174,694	4,306,394	Jun 10 07:00 PM
WG Biotech ApS	10% Owner	Jun 07	Sale	34.15	72,400	2,472,583	4,339,694	Jun 09 06:51 PM
Wedell-Wedellsborg Johan	Director	Jun 07	Sale	34.15	72,400	2,472,583	4,339,694	Jun 09 06:49 PM
Wedell-Wedellsborg Johan	Director	Jun 04	Sale	34.03	3,841	130,704	4,412,094	Jun 07 04:31 PM
Kruse Bo	EVP, CFO, Secretary & Treas.	Jun 04	Sale	33.48	4,000	133,920	249,077	Jun 07 04:30 PM
WG Biotech ApS	10% Owner	Jun 04	Sale	34.03	3,841	130,704	4,412,094	Jun 07 04:30 PM
WG Biotech ApS	10% Owner	Jun 03	Sale	33.19	30,666	1,017,670	4,415,935	Jun 07 04:30 PM
Wedell-Wedellsborg Johan	Director	Jun 03	Sale	33.19	30,666	1,017,670	4,415,935	Jun 07 04:31 PM
Wedell-Wedellsborg Johan	Director	Jun 01	Sale	35.57	6,864	244,173	4,446,601	Jun 02 04:32 PM
WG Biotech ApS	10% Owner	Jun 01	Sale	35.57	6,864	244,173	4,446,601	Jun 02 04:31 PM
WG Biotech ApS	10% Owner	May 28	Sale	36.34	25,000	908,475	4,453,465	Jun 02 04:31 PM
Wedell-Wedellsborg Johan	Director	May 28	Sale	36.34	25,000	908,475	4,453,465	Jun 02 04:32 PM
Gad Thomas	See remarks	May 28	Sale	36.95	4,000	147,813	1,603,927	Jun 01 04:32 PM
Kruse Bo	EVP, CFO, Secretary & Treas.	May 24	Sale	35.61	4,000	142,440	253,077	May 26 04:33 PM
Gad Thomas	See remarks	May 18	Sale	34.07	4,000	136,290	1,607,927	May 20 04:32 PM
Gad Thomas	See remarks	Apr 26	Option Exercise	2.00	7,000	14,000	7,000	Apr 28 04:16 PM
Gad Thomas	See remarks	Apr 26	Sale	27.96	7,000	195,730	0	Apr 28 04:16 PM
Gad Thomas	See remarks	Apr 12	Option Exercise	2.00	7,000	14,000	7,000	Apr 14 05:00 PM
Gad Thomas	See remarks	Apr 12	Sale	26.60	4,000	106,388	1,611,927	Apr 14 05:00 PM
Gad Thomas	See remarks	Apr 12	Sale	26.61	7,000	186,253	0	Apr 14 05:00 PM
Gad Thomas	See remarks	Apr 01	Option Exercise	2.00	9,000	18,000	9,000	Apr 05 04:35 PM
Gad Thomas	See remarks	Apr 01	Sale	30.27	6,000	181,615	1,615,927	Apr 05 04:35 PM
Gad Thomas	See remarks	Apr 01	Sale	30.26	9,000	272,331	0	Apr 05 04:35 PM
Gad Thomas	See remarks	Mar 15	Option Exercise	2.00	7,000	14,000	7,000	Mar 17 04:35 PM
Gad Thomas	See remarks	Mar 15	Sale	36.78	4,000	147,102	1,621,927	Mar 17 04:35 PM
Gad Thomas	See remarks	Mar 15	Sale	36.79	7,000	257,554	0	Mar 17 04:35 PM
Gad Thomas	See remarks	Mar 01	Option Exercise	2.00	9,000	18,000	9,000	Mar 03 04:31 PM
Gad Thomas	See remarks	Mar 01	Sale	35.50	6,000	213,029	596,000	Mar 03 04:31 PM
Gad Thomas	See remarks	Mar 01	Sale	35.51	9,000	319,611	0	Mar 03 04:31 PM
Gad Thomas	See remarks	Feb 16	Option Exercise	2.00	7,000	14,000	7,000	Feb 18 04:35 PM
Gad Thomas	See remarks	Feb 16	Sale	47.09	4,000	188,367	602,000	Feb 18 04:35 PM
Gad Thomas	See remarks	Feb 16	Sale	47.08	7,000	329,556	0	Feb 18 04:35 PM
Gad Thomas	See remarks	Feb 01	Option Exercise	2.00	7,000	14,000	7,000	Feb 03 05:50 PM
Gad Thomas	See remarks	Feb 01	Sale	41.97	4,000	167,888	606,000	Feb 03 05:50 PM
Gad Thomas	See remarks	Feb 01	Sale	41.99	7,000	293,897	0	Feb 03 05:50 PM
GILL DAVID N	Director	Jan 19	Option Exercise	11.16	2,000	22,320	2,000	Jan 20 04:16 PM
Gad Thomas	See remarks	Jan 19	Option Exercise	2.00	7,000	14,000	7,000	Jan 21 04:16 PM
Gad Thomas	See remarks	Jan 19	Sale	46.56	4,000	186,230	610,000	Jan 21 04:16 PM
Gad Thomas	See remarks	Jan 19	Sale	46.51	7,000	325,563	0	Jan 21 04:16 PM
GILL DAVID N	Director	Jan 19	Sale	46.52	2,000	93,045	0	Jan 20 04:16 PM
Gad Thomas	See remarks	Jan 05	Option Exercise	2.00	7,000	14,000	7,000	Jan 07 04:15 PM
Gad Thomas	See remarks	Jan 05	Sale	49.31	4,000	197,248	614,000	Jan 07 04:15 PM
Gad Thomas	See remarks	Jan 05	Sale	49.36	7,000	345,509	0	Jan 07 04:15 PM
Gad Thomas	See Remarks	Dec 28	Option Exercise	2.00	7,000	14,000	7,000	Dec 30 04:52 PM
Gad Thomas	See Remarks	Dec 28	Sale	51.98	7,000	363,833	0	Dec 30 04:52 PM
Gad Thomas	See Remarks	Dec 16	Option Exercise	2.00	7,000	14,000	7,000	Dec 17 04:39 PM
Gad Thomas	See Remarks	Dec 16	Sale	53.01	7,000	371,065	0	Dec 17 04:39 PM
Gad Thomas	See Remarks	Dec 14	Sale	52.89	4,000	211,546	618,000	Dec 16 06:06 PM
Gad Thomas	See Remarks	Dec 11	Option Exercise	2.00	50,000	100,000	50,000	Dec 14 04:30 PM
Gad Thomas	See Remarks	Dec 11	Sale	51.17	50,000	2,558,640	0	Dec 14 04:30 PM
Gad Thomas	See Remarks	Dec 10	Option Exercise	2.00	50,000	100,000	50,000	Dec 14 04:30 PM
Gad Thomas	See Remarks	Dec 10	Sale	50.75	50,000	2,537,620	0	Dec 14 04:30 PM
Moller-San Pedro Claus Juan	Chief Executive Officer	Dec 03	Sale	50.98	9,266	472,377	607,303	Dec 04 06:00 AM
Rajah Vignesh	SVP and CMO	Dec 02	Buy	51.03	233	11,890	1,697	Dec 04 06:00 PM
Moller-San Pedro Claus Juan	Chief Executive Officer	Dec 02	Sale	51.27	40,734	2,088,245	616,569	Dec 04 06:00 AM
Gad Thomas	President and Chairman	Dec 01	Sale	51.42	4,000	205,685	622,000	Dec 02 04:15 PM
GILL DAVID N	Director	Nov 18	Option Exercise	11.16	2,000	22,320	2,000	Nov 20 04:15 PM
GILL DAVID N	Director	Nov 18	Sale	45.77	2,000	91,530	0	Nov 20 04:15 PM
Rajah Vignesh	SVP and CMO	Nov 17	Buy	45.74	1,464	66,963	1,464	Dec 04 06:00 PM
Gad Thomas	President and Chairman	Nov 16	Sale	46.17	4,000	184,672	626,000	Nov 17 04:15 PM
GILL DAVID N	Director	Nov 03	Option Exercise	11.16	4,000	44,640	4,000	Nov 05 05:51 PM
GILL DAVID N	Director	Nov 03	Sale	45.00	4,000	180,000	0	Nov 05 05:51 PM
Gad Thomas	President and Chairman	Nov 02	Sale	43.69	4,000	174,769	630,000	Nov 05 04:36 PM
Gad Thomas	President and Chairman	Oct 15	Sale	39.15	4,000	156,604	634,000	Oct 19 04:15 PM
Gad Thomas	President and Chairman	Oct 01	Sale	38.88	4,000	155,524	638,000	Oct 02 05:38 PM
Gad Thomas	President and Chairman	Sep 15	Sale	40.81	4,000	163,225	642,000	Sep 17 04:15 PM
Gad Thomas	President and Chairman	Sep 14	Option Exercise	2.00	22,569	45,138	22,569	Sep 15 04:15 PM
Gad Thomas	President and Chairman	Sep 14	Sale	41.00	22,569	925,426	0	Sep 15 04:15 PM
Gad Thomas	President and Chairman	Sep 11	Option Exercise	2.00	13,571	27,142	13,571	Sep 15 04:15 PM
Gad Thomas	President and Chairman	Sep 11	Sale	40.33	13,571	547,331	0	Sep 15 04:15 PM
Gad Thomas	President and Chairman	Sep 10	Option Exercise	2.00	13,860	27,720	13,860	Sep 15 04:15 PM
Gad Thomas	President and Chairman	Sep 10	Sale	41.58	13,860	576,360	0	Sep 15 04:15 PM
Gad Thomas	President and Chairman	Sep 01	Sale	41.60	4,000	166,390	646,000	Sep 02 04:15 PM
Gad Thomas	President and Chairman	Aug 17	Sale	40.35	4,000	161,392	650,000	Aug 19 04:16 PM
Gad Thomas	President and Chairman	Aug 12	Sale	39.51	13,000	513,636	654,000	Aug 13 04:15 PM
Gad Thomas	President and Chairman	Aug 11	Sale	40.06	37,000	1,482,042	667,000	Aug 13 04:15 PM
Gad Thomas	President and Chairman	Aug 03	Sale	36.51	4,000	146,026	704,000	Aug 05 04:25 PM
Gad Thomas	President and Chairman	Jul 15	Sale	40.06	4,000	160,229	708,000	Jul 17 04:18 PM
Gad Thomas	President and Chairman	Jul 01	Sale	42.04	4,000	168,178	712,000	Jul 06 04:15 PM
Gad Thomas	President and Chairman	Jun 15	Sale	43.45	4,000	173,811	716,000	Jun 16 06:14 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience